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Preeclampsia (PE) is responsible for about 20% of the 13 million preterm births each year 
worldwide, including 100,000 cases annually in the United States. Despite being a leading cause 
of maternal and perinatal morbidity, the mechanisms of pathogenesis are still largely unknown. 
PE is progesterone deficient state characterized by hypertension, chronic immune activation, 
endothelial dysfunction and severe forms can lead to seizures. Treatment of seizures includes the 
administration of magnesium sulfate (MgSO4) though not all PE patients are responsive, and it 
does not decrease PE-associated hypertension. To resolve these conditions, PE patients are 
delivered early thereby making PE the leading cause for fetal mortality and morbidity 
worldwide. Hypothesizing that the reduced progesterone levels accounted for the onset of 
hypertension in PE, the effects of both 17-hydroxyprogesterone caproate (17-OHPC) and 
Progesterone Induced Blocking Factor (PIBF) were studied in hypertensive pregnant rat models 
of PE. Following the intervention, blood pressure and endothelin-1 were reduced while nitric 
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 Preeclampsia (PE) is a multifactorial hypertensive disease that affects and complicates up 
to 8% of pregnancies in the United States and 12% in Mississippi and is responsible for one-fifth 
of all the preterm births in the United States annually5,7.  
While PE results in high levels of maternal and perinatal morbidity, the only treatment 
currently available is preterm delivery16. To allow for the development of mechanism-based 
therapies to better manage patients with PE, efforts to identify the key components in the 
pathogenesis of PE at the molecular level are currently underway. Findings from these prior 
studies have discovered that PE is associated by decreased levels of progesterone, new onset 
hypertension, chronic inflammation, mitochondrial dysfunction, and endothelial dysfunction2 
(Figure 1). These PE-associated changes are typically diagnosed near the 20th week of pregnancy 
to third trimester during pregnancy.  
 During the third trimester of a normal pregnancy, progesterone levels are measured to be 
about 34 ng/mL9. In pregnant women with PE, this increase is not observed (15 ng/mL; Figure 
2). A key signaling molecule during pregnancy, progesterone has the potential to impact a 
number of physiological processes in pregnant women. As part of regulating the progesterone-
dependent pathways, the body releases factors like Progesterone Induced Blocking Factor (PIBF) 
which helps to control proinflammatory mechanisms that occur early in gestation. PIBF then 
goes on to stimulate Interleukin 4 (IL-4) and therefore increase Th2 cytokines. IL-4 and Th2 
cytokines are thought to promote a more tolerant, anti-inflammatory environment that protects 
the fetus. PIBF in women without PE, also helps to crease cytolytic natural killer (NK) cells as 
well as Th1 cytokines (Figure 3, 4). Thus if, progesterone is decreased then likewise, so is PIBF 
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and these inflammatory processes are not appropriately regulated. 17-ortho hydroxyprogesterone 
(17-OHP) is a progesterone that is mainly produced by the adrenal glands, gonads, and ovaries 
(Figure 5). Clinically, 17-orthohydroxyprogesterone caproate (17-OHPC) is a synthetic 
progesterone that is currently utilized for treating preterm labor in pregnant women without PE. 
However, due to the lack of clinical data, it is not yet used as a treatment for PE6, 13-14. 
Mitochondrial oxidative stress refers to the production of more than normal amounts of 
reactive oxygen species (ROS) from the mitochondria. Circulating factors such as inflammatory 
cytokines and cells induce mitochondrial dysfunction in a preeclamptic placenta which can lead 
to a high instance of mitochondrial DNA damage as well as impaired function of the 
mitochondria in the electron transport chain2.  
Endothelial dysfunction is a condition in which the endothelial layer (the inner lining) of 
the small arteries fails to perform all of its important functions normally. It is characterized by 
increased levels of sFlt-1 and ET-1, as well as a decrease in levels of nitric oxide (NO). sFlt-1 is 
a soluble vascular endothelial growth receptor (VEGFR1). VEGF is important in maintaining the 
vascular endothelium but is antagonized by sFlt-1 during PE (Figure 6). Endothelin-1 is a potent 
vasoconstrictor while nitric oxide is a vasodilator11. This results in a strong correlation leading to 
increased levels of ET-1 and decreased levels of NO. This imbalance leads to chronic 
vasoconstriction. 
During early stages of pregnancy complicated by preterm labor, but not preeclampsia, 17-
OHPC is given to patients as early as 20 weeks13,14. 17-OHPC is delivered to these patients 
weekly in order to prolong labor and has increased time to delivery, yet there is no 

















Figure 1: Factors Contributing to Preeclampsia18 
There are several factors that contribute to placental dysfunction such as a genetic 
component, Angiotensin II Type-1 Receptor Autoantibodies, Natural Killer cells, 
oxidative stress, and various other factors. Placental dysfunction leads to an excess of 
sFlt-1 and soluble endoglin (sEng) as well as increased growth restriction of the fetal 
unit. The outcomes of this are hypertension, proteinuria, and various other complications. 






Figure 2: Progesterone Levels in Normal Pregnancy Versus Preeclampsia9 
The graph above demonstrates the levels of circulating progesterone in a normal 
pregnancy versus during preeclampsia. In normal pregnancy, plasma progesterone levels 
are around 34 ng/ml, whereas preeclamptic patients have significantly lower levels 











Figure 3: PIBF Levels in Normal Pregnancy Versus Preeclampsia19 
Progesterone Induced Blocking Factor (PIBF) in normal pregnancy increases to level 
around 110 ng/ml in the 30-37-week period of gestation. During preterm labor, PIBF 
concentration is significantly lower with its highest concentration being around 10 ng/ml 





Figure 4: PIBF Diagram10 
During pregnancy, progesterone activates Progesterone Induced Blocking Factor (PIBF), 
which goes on to initiate a series of events. PIBF inhibits T-helper type 1 (Th1) cells, 
lowering levels of interleukin-2 (IL-2), interleukin-12 (IL-12), and Tumor Necrosis 
Factor alpha (TNF⍺). PIBF also inhibits Natural Killer (NK) cells. T-helper type 2 (Th2) 
cells are activated which promotes interleukin-4 (IL-4), interleukin-6 (IL-6), and 
interleukin-10 (IL-10). PIBF also activates B cells, or B lymphocytes, to help with 





















Figure 5: Progesterone and 17-OHPC Structures  
The structural formulas shown are natural progesterone produced in the body, 17-alpha-
hydroxyprogesterone with is a natural progestin, and 17-hydroxyprogesterone caproate 

















Figure 6: sFlt-1 and VEGF22 
sFlt-1 is one of the main contributors to placental dysfunction. In a normal pregnancy, 
Vascular Endothelial Growth Factor binds to its FLT1 receptor. This, in turn, promotes 
angiogenesis, or the development of new blood vessels. During preeclampsia, an excess 
of the soluble fms-like tyrosine kinase receptor binds VEGF, creating an antiangiogenetic 










Inducing Hypertension via the sFlt-1 Model 
The pregnant Sprague-Dawley rats used for this study were obtained from Harlan 
Sprague Dawley in Indianapolis, Indiana (Figure 7A). The rats were kept in housing conditions 
that consisted of a 23°C temperature room with access to food and water. Animals weighing 
200-250g were randomly assigned to Normal Pregnant (NP; control) or NP + sFlt-1 groups. On 
day 13 of gestation, the NP + sFlt-1 group rats were put under anesthesia in order to place the 
sFlt-1 mini osmotic pump into the abdominal cavity to induce hypertension (Figure 7B). This 
pump dosage was designated as 3.7 µm·kg-1·day-1 for 6 days, the 6 days representing days 13-19 
of the animals’ gestation period. After the animals’ abdominal cavities were sutured, analgesics 
were applied via subcutaneous injection of 5 mg/kg Carprofen once a day for 2 to 3 days. All 
experimental procedures performed in this study were executed in accordance with the National 
Institute of Health guidelines developed for the use and care of animals. All protocols were 
approved by the Institutional Animal Care and Use Committee at the University of Mississippi 
Medical Center. Surgical procedures were carried out under the appropriate anesthesia and 
analgesics were give post-operatively as needed, under the supervision of the veterinary staff.  
17-OHPC Administration  
 On day 15 and 18 of gestation, a group of NP + sFlt-1 treated rats were intraperitoneally 
injected with 17-OHPC. The solution dosage administered was 0.5 cm3 solution of 3.32 mg/kg9. 
The NP rat group were not treated with an injection of 17-OHPC because the previous studies 
demonstrate no effect on blood pressure or other molecular factors in NP rats3 and is therefore 
seen as an unnecessary procedure for the rat.  
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PIBF Administration 
 On day 15 of gestation, a group of NP + sFlt-1 treated animals were intraperitoneally 
injected with PIBF at a dosage of 2.0 µm/mL. This dosage was chosen from previous 
experiments inducing hypertension with the Reduced Uterine Perfusion Pressure (RUPP) model. 
These experiments showed that the appropriate in vivo dosage was 2.0 µm/mL in order to 
decrease signs of preeclampsia in response to elevated sFlt-1 during pregnancy.  
Mean Arterial Blood Pressure Measurement  
 On day 19 of gestation, the animals were placed under isoflurane anesthesia so carotid 
arterial catheters could be inserted in order to measure blood pressure. The catheters were placed 
into the carotid artery towards the back of the animal’s neck to be made available externally. 
Blood pressure was then measured via a pressure transducer and recorded for 30 minutes after a 
30-minute stabilization period. After measuring MAP, the animal’s tissues were harvested, blood 
samples were collected, and pup and placenta weights were recorded.  
Measuring Nitrate-Nitrite Levels 
 Plasma, obtained from the collected blood samples, was used in order to measure the 
circulating nitrate-nitrite levels using the Nitrate/Nitrite Colorimetric Assay Kit from Cayman 
Chemical (Ann Arbor, MI). Instructions that were induced were followed. The inter-assay 
coefficient of variation is 3.4% while intra-assay coefficient of variation is 2.7%.2 
Measuring Renal Cortex Preproendothelin-1 mRNA Levels  
 In order to measure renal cortex preproendothelin-1 (PPET-1) levels, real-time 
polymerase chain reaction (RT-PCR) was used. The tissue samples from the kidney were stored 
in a -80°C freezer. Tissue samples were homogenized, and RNA was extracted using the RNeasy 
Protect Mini Kit from QIAGEN (Germantown, MD). A spectrophotometer was used in order 
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determine the concentration and the quality of the RNA. RT-PCR was performed using iQ 
SYBR Green Supermix and CFX96 Touch Real-Time PCR Detection System from Bio-Rad 
Laboratories (Hercules, CA). The primer sequences for PPET that were used are 
CTAGGTCTAAGCGATCCTTG forward and TCTTTGTCTGCTTGGC reverse.2 
Measuring Mitochondrial Dysfunction 
 Placentas and renal samples taken from NP + sFlt-1 + PIBF animals were utilized in 
order to establish the peroxide production of the mitochondria. These sample were put into a 
mechanical homogenizer to lyse the cells. Next, the lysed cells are put through a centrifugation 
process in order to extract the mitochondria. After this, sample are put through an Oxygraph-2K 
to measure the amount of respiration or a fluorescence microplate reader in order to measure 
mitochondrial peroxide. An amplex red assay was used where samples were placed on a 96 well 
plate and put into a fluorescence microplate reader (Figure 8). The samples were incubated with 
a respiration buffer, superoxide dismutase, horseradish peroxidase, and succinate. Amplex red 
was added to start the reaction and the real-time production of peroxide was recorded. There 
were also wells without amplex red in order to serve as a control.  
Measuring Mitochondrial ROS23 
 In order to determine the amount of mitochondrial reactive oxygen species, MitoSOX red 
dye was utilized. Serum obtained from the rats was used to determine mitochondrial ROS 
production with human umbilical venous endothelial cells (HUVECs). Human umbilical venous 
endothelial cells (HUVECs) were grown in HUVEC media and then cultured in a 6-well plate 
and incubated overnight, in order to determine the vascular endothelial cell mitochondria 
function. After incubation, these cells were washed and then incubated with MitoSOX red. Cells 
were then washed with Dulbecco’s phosphate-buffered saline (DPBS) two times and incubated 
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again in a serum free medium for 4 hours. After this, flow cytometry was utilized in order to 
collect and analyze the cells. The basis of this assay is to determine if circulating factors mediate 
endothelial mitochondrial dysfunction.  
Statistical Analysis 
All of the data are expressed as mean ± SEM. Comparisons of control with experimental 
groups were analyzed by One-way ANOVA with Bonferroni multiple comparisons test as post 





















Figure 7: Sprague-Dawley Rat and Incision Site 
For this experiment, pregnant Sprague-Dawley rats were obtained from Harlan Sprague 
Dawley in Indianapolis, Indiana (A). On the right, is a visual representation of the 
































MAP was significantly increased in NP + sFlt-1 rats 117 ± 1 mmHg (n=13) 
compared to the NP control rats 99 ± 2 mmHg (n=12, p < 0.05). After administering 17-
OHPC to these sFlt-1 treated rats, the MAP was significantly reduced to 102 ± 3 mmHg 
(n=8) (Figure 9). 17-OHPC showed no changes in either placental or pup weight in 
response to sFlt-1 or 17-OHPC during pregnancy (Figure 10). Recent study has shown 
that 17-OHPC, when given to NP rats, shows no change to either placental or pup 
weights3.  
In the NP + sFlt-1 treated rats, the renal cortex PPET-1, which is a marker for ET-
1, showed a 3-fold increase compared to the NP animals. After administration of 17-
OHPC, PPET-1 levels were significantly reduced (n = 5-7/group, p < 0.05) (Figure 11).  
Plasma nitrate-nitrite levels were 44 ± 9 µM in NP rats (n = 9), 20 ± 3 µM in NP 










Figure 9: 17-OHPC Mean Arterial Pressure Graph2 
Normal pregnant (NP) the mean arterial blood pressure (MAP) is 99 ± 2 mmHg (n=12). 
When sFlt-1 is administered, the blood pressure is significantly increased to 117 ± 1 
mmHg (n=13) compared to the NP group (p < 0.05). When the sFlt-1 group was treated 


































































Figure 10: 17-OHPC Pup and Placenta Weight Graph2 
Pup weight (left) did not differ between treatment groups: NP (n=12), NP + sFlt-1 
(n=13), and NP + sFlt-1 + 17-OHPC (n=8). The graph of the right represents placenta 
weight in grams. No significant difference was observed in placenta weight either (right 
graph), although there is a slight upward trend between the sFlt-1 administered group 













Figure 11: 17-OHPC Renal Cortex PPET-1 and Nitrate-Nitrite Graph2 
 
Renal cortex preproendothelin-1 (PPET-1) levels were measured (left graph) and the sFlt-
1 administered group showed a significant increase in PPET-1 compared to the NP group. 
When treated with 17-OHPC, PPET-1 levels were significantly lowered compared to the 
sFlt-1 group (n = 5-7/group, p < 0.05). Circulating plasma nitrate-nitrite was measured 
(right graph) with a level of 44 ± 9 µM in NP rats (n = 9), 20 ± 3 µM in NP + sFlt-1 (n = 














Mean arterial pressure (MAP) was increased in s-Flt-1 rats to 112 ± 2 mmHg (n = 9) 
compared to control NP rats 98 ± 2 mmHg (n = 10, p < 0.05). Administration of PIBF reduced 
MAP to 100 ± 1 mmHg in the presence of s-Flt-1 (n = 9, p < 0.05) (Figure 12). There was also 
no change to pup weight between the NP, sFlt-1 treated, and PIBF treated animals (Figure 13). 
Body weights were NP rats (317 ± 9.32 grams), s-Flt-1 rats (322 ± 8.07 grams), and s-Flt-1 rats 
administered with PIBF (303 ± 6 grams). 
PIBF was shown to reduce PPET-1 in response to elevated sFlt-1 during pregnancy, 
which was done by real-time PCR. In both the placenta and the renal cortex, there was an 
increase of endothelin-1 levels in the sFlt-1 treated rats compared to the NP rats. When treated 
with PIBF, these rats had a significant decrease in levels of endothelin-1 compared to the sFlt-1 
treated rats (Figure 14). 
The nitrate-nitrite levels in the sFlt-1 treated rats were significantly lower than the NP 
rats, but there was not a significant difference in the nitric oxide levels of the PIBF treated rats 
(Figure 15). 
Placental mitochondrial state 3 respiration decreased in NP + s-Flt-1 infused rats (n = 3) 
(206 ± 67 pmol of O2/sec/mg, n = 4) compared to NP controls (n = 3) (268 ± 24 pmol of 
O2/sec/mg). State 3 placental respiration in NP + sFlt-1 rats administered PIBF (n=5) (309 ± 153 
pmol of O2/sec/mg) was elevated compared to NP + sFlt-1 rats. Uncoupled respiration also 
decreased in NP + s-Flt-1 infused rats (n=3) (87 ± 42 pmol of O2/sec/mg, n=4) compared to NP 
controls (n=3) (164 ± 21 pmol of O2/sec/mg, n=3) and NP + sFlt-1 rats administered PIBF (n=5) 
(199 ± 93 pmol of O2/sec/mg, n=5) (Figure 16).  
No effect was shown on renal mitochondrial reactive oxygen species and respiration with 





Figure 12: PIBF Mean Arterial Pressure Graph 
Mean arterial pressure (MAP) for the PIBF treated rats. The sFlt-1 group showed 
significant increase in blood pressure at to 112 ± 2 mmHg (n = 9) compared to the NP 
group 98 ± 2 mmHg (n = 10, p < 0.05). The PIBF treated group indicated a significantly 

































Figure 13: PIBF Pup Weight Graph 
 
There was no difference in pup weight from the normal pregnant, sFlt-1 administered, 




































Figure 14: PIBF Placenta and Renal Cortex PPET-1 Graph 
 
Placenta PPET-1 was measured in the graph to the right. In the sFlt-1 administered group 
significantly high levels of PPET-1 were seen as compared to the normal pregnant group. When 
treated with PIBF, PPET-1 levels were decreased compared to the sFlt-1 group. On the left 
graph, renal cortex PPET-1 levels were measured. When the rats were given sFlt-1 the PPET-1 
levels were increased significantly from the NP group. When treated with PIBF, the levels of 








































































































Figure 15: PIBF Circulating Nitrate-Nitrite Graph 
 
A significant decrease was seen in circulating nitrate-nitrite in the sFlt-1 group compared to the 
normal pregnant group. When looking at the PIBF treated group, no change was seen compared 

































Figure 16: PIBF Placenta Mitochondria ROS and Respiration Graph  
 
For placental mitochondria Reactive Oxygen Species (ROS; top graph), in the sFlt-1 group there 
was an increase in ROS compared to the NP group. The PIBF treated group displayed a 
significant decrease in ROS contrasted to the sFlt-1 group. No significant difference in placental 
mitochondria respiration (bottom right/left graphs) was seen, although the data suggests that 











Figure 17: PIBF Kidney Mitochondria ROS and Respiration Graph  
 














































































 A crucial part of a healthy pregnancy is the production of the hormone progesterone and 
therefore the activation of Progesterone Induced Blocking Factor (PIBF). With lower levels of 
progesterone and PIBF in preeclamptic patients comes other risk factors that makes it difficult to 
have a full-term pregnancy. A person with preeclampsia shows symptoms of chronic 
inflammation, high blood pressure, mitochondrial dysfunction, and endothelial dysfunction. This 
consistent rise in blood pressure increases the risk of stroke, liver or kidney rupture and other 
organ damage for the mother, making it a necessity to deliver the baby early.  
According to the data shown, infusing sFlt-1 into pregnant animals stimulates many 
characteristics of preeclampsia. Because the only management option for preeclampsia is an 
intravenous injection of magnesium sulfate, which does not treat these symptoms, it is essential 
to find a treatment to increase vasodilatory factors and decrease vasoactive factors and thus 
hypertension for the mother. The only treatment available is early delivery of the fetus.  
In order to increase vasodilatory factors such as nitric oxide and decrease vasoactive 
factors such as endothelin-1, 17-orthohydroxyprogesterone caproate, a synthetic progesterone, 
was used to mimic the effects of natural progesterone. Moreover, we hypothesized that the 
administration of Progesterone Induced Blocking Factor, a protein resulting from progesterone 
activating the progesterone receptor, would improve circulating factors such as nitric oxide and 
endothelin and therefore improve renal and placental mitochondrial function. Taken together, 
these factors would decrease maternal mean arterial blood pressure thereby allowing the 
pregnancy to continue.   
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 According to the data collected, this study demonstrates that 17-OHPC improves 
hypertension, circulating nitrate-nitrite, and endothelin-1. In addition, PIBF, a product of 
progesterone signaling, safely decreases levels of endothelin-1, blood pressure, and placental 
mitochondrial reactive oxygen species. Thus, PIBF may be the mechanism whereby 17-OHPC 
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